Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

被引：0
|
作者：
Wang, Zongren [1 ]
Zhan, Wenhao [1 ]
Huang, Bin [1 ]
Luo, Cheng [1 ]
Chen, Lingwu [1 ]
Chen, Junxing [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-183-138-226-9326; 613-135-2370-7650-2454; 613-4678-146-11576; 613-135-244-3829; 6; 5; 4; 3; 2; 158; 2424; 1714; 76; 62; 1; 38092-20390; 38092-29187;
D O I：
10.1200/JCO.2024.42.4_suppl.618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：618 / 618
页数：1
相关论文
共 50 条
  • [31] BLADDER BIOPSY AT 3 MONTHS POST-BACILLUS CALMETTE-GUERIN (BCG) INDUCTION FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) IS NOT CORRELATED WITH ONCOLOGICAL OUTCOMES
    Zhang, Mimi
    Godoy, Guilherme
    Lerner, Seth
    JOURNAL OF UROLOGY, 2013, 189 (04): : E731 - E731
  • [32] Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG): Updated follow-up from KEYNOTE-057.
    De Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Krieger, Laurence Eliot Miles
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Maintenance Bacillus Calmette-Guerin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer
    Lamm, Donald
    Persad, Raj
    Colombel, Marc
    Brausi, Maurizio
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (09) : 715 - 734
  • [34] Combination Therapy for High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) with and without BCG Pretreatment
    Rexer, Heidrun
    Grimm, Marc-Oliver
    Ohlmann, Carsten-H.
    AKTUELLE UROLOGIE, 2024, 55 (05) : 412 - 413
  • [35] The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?
    Hofbauer, Sebastian L.
    Shariat, Shahrokh F.
    Chade, Daher C.
    Sarkis, Alvaro S.
    Ribeiro-Filho, Leopoldo A.
    Nahas, Willian C.
    Klatte, Tobias
    UROLOGIA INTERNATIONALIS, 2016, 96 (01) : 46 - 50
  • [36] Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin: Extended follow-up of KEYNOTE-057 cohort A.
    Balar, Arjun Vasant
    Kamat, Ashish M.
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Krieger, Laurence Eliot Miles
    Singer, Eric A.
    Bajorin, Dean F.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Zambon, Joao Paulo
    Kapadia, Ekta
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [37] COFORMULATED VIBOSTOLIMAB/PEMBROLIZUMAB OR COFORMULATED FAVEZELIMAB/PEMBROLIZUMAB FOR BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): COHORT C OF PHASE 2 KEYNOTE-057 TRIAL
    Shilpa, Gupta
    Neal, Shore
    Girish, Kulkarni
    Andrea, Necchi
    Hema, Dave
    Ekta, Kapadia
    Qing, Zhao
    Ashish, Kamat
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [38] Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor
    Huang, Bin
    Huang, Gaowei
    Li, Wenji
    Chen, Lingwu
    Mao, Xiaopeng
    Chen, Junxing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (06) : 1781 - 1788
  • [39] Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor
    Bin Huang
    Gaowei Huang
    Wenji Li
    Lingwu Chen
    Xiaopeng Mao
    Junxing Chen
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1781 - 1788
  • [40] Phase Ib study: APL-1202 (APL) in combination with Bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC).
    Sfakianos, John
    Shore, Neal D.
    Zhuang, John
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345